INn my opinion if the announcement is correct, the FDA has done a complete about face from its position in that notorious letter. It is suggesting that the evidence shows Leronlimab is effective enough to warrant further study. This is a huge change in its previous official position. It also indicates that the FDA, or some part of it, wants to be seen as part of the solution, not part of the problem. It is happening at a very critical time.